Search Results - "Mordec, Kasia"

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers by Nichols, Robert J., Haderk, Franziska, Stahlhut, Carlos, Schulze, Christopher J., Hemmati, Golzar, Wildes, David, Tzitzilonis, Christos, Mordec, Kasia, Marquez, Abby, Romero, Jason, Hsieh, Tientien, Zaman, Aubhishek, Olivas, Victor, McCoach, Caroline, Blakely, Collin M., Wang, Zhengping, Kiss, Gert, Koltun, Elena S., Gill, Adrian L., Singh, Mallika, Goldsmith, Mark A., Smith, Jacqueline A. M., Bivona, Trever G.

“…Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAF…”
Get full text

Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression by Ventura, Richard, Mordec, Kasia, Waszczuk, Joanna, Wang, Zhaoti, Lai, Julie, Fridlib, Marina, Buckley, Douglas, Kemble, George, Heuer, Timothy S.

“…Inhibition of de novo palmitate synthesis via fatty acid synthase (FASN) inhibition provides an unproven approach to cancer therapy with a strong biological…”
Get full text

FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression by Heuer, Timothy S., Ventura, Richard, Mordec, Kasia, Lai, Julie, Fridlib, Marina, Buckley, Douglas, Kemble, George

“…Palmitate, the enzymatic product of FASN, and palmitate-derived lipids support cell metabolism, membrane architecture, protein localization, and intracellular…”
Get full text

Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment by Quintana, Elsa, Schulze, Christopher J., Myers, Darienne R., Choy, Tiffany J., Mordec, Kasia, Wildes, David, Shifrin, Nataliya Tobvis, Belwafa, Amira, Koltun, Elena S., Gill, Adrian L., Singh, Mallika, Kelsey, Stephen, Goldsmith, Mark A., Nichols, Robert, Smith, Jacqueline A.M.

“…Abstract The protein tyrosine phosphatase SHP2 binds to phosphorylated signaling motifs on regulatory immunoreceptors including PD-1, but its functional role…”
Get full text

Abstract 5019: Allosteric inhibition of SHP2 suppresses CSF1R signaling and selectively reduces viability of M2 tumor associated macrophages contributing to anti-tumor immunity by Quintana, Elsa, Schulze, Chris J., Choy, Tiffany J., Myers, Darienne R., Mordec, Kasia, Daniel, Dylan, Goldsmith, Mark A., Smith, Jan A.

“…Abstract The protein-tyrosine phosphatase SHP2 promotes oncogenic RAS/MAPK pathway activation in different tumor types. In immune cells, SHP2 binds to…”
Get full text

Abstract 3314: Molecular profiling of covalent menin inhibitor, BMF-219, in KRAS-mutated solid tumors by Momin, Amin A., Rughwani, Tripta, Tanataweethum, Nida, Mordec, Kasia, Lin, Raechel, Chin, Megan, Lu, Daniel, Somanath, Priyanka, Balakrishnan, Mini, Butler, Thomas

“…Abstract Menin is an epigenetic protein that drives oncogenic function through transcriptional control directed by its various cofactors such as MLL1 (KMT2A)…”
Get full text

Abstract C175: FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640 by Heuer, Timothy S., Ventura, Richard, Mordec, Kasia, Lai, Julie, Waszczuk, Joanna, Rubio, Claudia, O' Farrell, Marie, Buckley, Douglas, Kemble, George

“…Abstract Tumor cells have an increased dependence on FASN-synthesized palmitate compared to non-tumor cells, which obtain many of their required lipids from…”
Get full text

Abstract 4878: RMC-4550, an allosteric inhibitor of SHP2: Synthesis, structure, and anti-tumor activity by Koltun, Elena S., Aay, Naing, Buckl, Andreas, Jogalekar, Ashutosh S., Kiss, Gert, Marquez, Abby, Mellem, Kevin T., Mordec, Kasia, Saldajeno-Concar, Mae, Semko, Chris M., Tibrewal, Nidhi, Tzitzilonis, Christos, Won, Walter, Smith, Jacqueline A., Wilson, Susan E., Nichols, Robert J., Wang, Zhengping, Wilds, David, Singh, Mallika, Gill, Adrian L.

“…Abstract Genetic and pharmacologic evidence has shown that SHP2, a non-receptor protein tyrosine phosphatase (PTP) and scaffold protein encoded by the PTPN11…”
Get full text

Abstract 4446: Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis by Heuer, Timothy S., Ventura, Richard, Mordec, Kasia, Lai, Julie, Waszczuk, Joanna, Hammonds, Glenn, Fridlib, Marina, Johnson, Russell, Hu, Lily, Wagman, Allan, O'Farrell, Marie, Buckley, Douglas, Kemble, George

“…Abstract Inhibition of de novo palmitate synthesis by fatty acid synthase (FASN) is a novel cancer therapeutic approach with strong biological rationale. Tumor…”
Get full text

Abstract 1815: Efficacy of FASN-selective small molecule inhibitors in preclinical tumor models by Heuer, Timothy S., Ventura, Richard, Waszczuk, Joanna, Mordec, Kasia, Lai, Julie, Johnson, Russell, Hu, Lilly, Cai, Haiying, Wagman, Allan, Buckley, Douglas, Parish, Stanley T., Bruckheimer, Elizabeth, Kemble, George

“…Abstract Fatty acid synthase (FASN) expression increases with tumor progression and is associated with impaired response to chemotherapy and diminished patient…”
Get full text

Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment by Quintana, Elsa, Schulze, Christopher J, Myers, Darienne R, Choy, Tiffany J, Mordec, Kasia, Wildes, David, Tobvis Shifrin, Nataliya, Belwafa, Amira, Koltun, Elena S, Gill, Adrian L, Singh, Mallika, Kelsey, Stephen, Goldsmith, Mark A, Nichols, Robert, Smith, Jacqueline A M

“…The protein-tyrosine phosphatase SHP2 binds to phosphorylated signaling motifs on regulatory immunoreceptors including PD-1, but its functional role in tumor…”
Get full text

Effect of 2-Deoxyglucose, a Glycolytic Inhibitor, on the ATP Levels and Viability of B Lymphocytes from Subjects with Chronic Lymphocytic Leukemia (CLL) by Tidmarsh, George F., Tanner, Laura I., O'Connor, Julie, Eng, Clarence, Mordec, Kasia

“…One hallmark of tumor cells is a high rate of glycolysis, which underlies the utility of the glucose analog, 2-[18]fluoro-2-deoxyglucose for PET imaging of…”
Get full text